RecruitingPhase 2NCT07693452

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

Sponsor

University of California, Irvine

Enrollment

15 participants

Start Date

Jun 18, 2026

Study Type

INTERVENTIONAL

Conditions

Pseudomyxoma Peritonei Appendiceal Mucinous Neoplasm

Summary

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Metformin for people with appendiceal mucinous neoplasm and pseudomyxoma peritonei. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetformin

Given PO

Locations(1)

Chao Family Comprehensive Cancer Center, University of California, Irvine

Orange, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07693452

Related Trials

Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)

NCT065130651 location

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis

NCT040249171 location